Obviousness — US Patent 12083103

Obviousness Analysis of US Patent 12,083,103 under 35 U.S.C. § 103

This analysis evaluates the obviousness of US Patent 12,083,103, titled "Tacrolimus for improved treatment of transplant patients," under 35 U.S.C. § 103, considering prior art available before the patent's priority date of May 30, 2007.

General Motivation for a Person Having Ordinary Skill in the Art (PHOSITA):

Prior to May 30, 2007, a PHOSITA in pharmaceutical formulation and transplant medicine was acutely aware of the significant challenges associated with tacrolimus therapy. Immediate-release formulations like Prograf® (FDA approved 1994, label April 27, 2006) were known to exhibit large inter- and intra-individual variability in absorption, low bioavailability (around 20%), require frequent dose adjustments based on trough levels, and cause significant dose-related side effects, including nephro- and neurotoxicity. The approval of Advagraf® (an extended-release, once-daily tacrolimus) by the EMEA on April 23, 2007, signaled a clear industry trend toward developing improved, once-daily formulations to enhance patient compliance and drug safety. The overarching motivation for a PHOSITA would be to develop tacrolimus formulations that offer more predictable pharmacokinetic profiles, reduce side effects, and improve therapeutic outcomes for transplant patients.

Claim 1 Obviousness Analysis: Extended Release Formulation with Specific Dissolution Profile

Claim 1: A method for immunosuppressive treatment comprising once-daily oral administration of a solid oral dosage form of tacrolimus, characterized by releasing at most 63.5% of the active substance within 12 hours when tested under specific USP II (paddle) or USP I (basket) dissolution conditions (pH 4.5, 0.005% hydroxypropylcellulose, 50 rpm).

Combination of Prior Art: WO 2005/020993 in view of Advagraf® and general pharmaceutical knowledge.

WO 2005/020993 (published March 10, 2005) by the same inventors, discloses sustained-release tacrolimus formulations with improved bioavailability compared to Prograf®. This prior art explicitly teaches formulations with a T63.6% (time to 63.6% release) ranging from 1.9 to 8.2 hours. A formulation that releases 63.6% of tacrolimus in 8.2 hours is already significantly extended.
Advagraf® (approved by EMEA April 23, 2007) established the commercial viability and clinical need for a once-daily extended-release tacrolimus product.
General pharmaceutical knowledge includes the routine application of standard dissolution testing methods, such as USP I (basket) and USP II (paddle). The patent itself describes these as "preferred methods" and "conventional dissolution methods used for tacrolimus dosage forms". Furthermore, the modulation of dissolution rates by adjusting excipient types and concentrations (e.g., polymers like hydroxypropylcellulose, waxes, or components for solid dispersions as taught in WO 2005/020993 and WO 2005/020994) is a standard technique in pharmaceutical formulation.

Motivation and Rationale:
A PHOSITA would be motivated to optimize existing extended-release tacrolimus formulations, building upon the advancements demonstrated in WO 2005/020993 and the commercial availability of Advagraf®. The goal would be to achieve a more consistently sustained release profile over a full 24-hour dosing interval, aiming to further mitigate peak-related side effects and ensure adequate trough levels for continuous immunosuppression.

The specific dissolution parameter of "at most 63.5% release in 12 hours" represents a further extension of the release profile. Given that WO 2005/020993 already disclosed formulations achieving 63.6% release in 8.2 hours, a PHOSITA would have a reasonable expectation of successfully developing a formulation that releases less than 63.5% in 12 hours through routine optimization of excipient types and ratios (e.g., increasing the amount of a release-retarding polymer or adjusting its properties). The specified dissolution test conditions are explicitly stated as conventional for tacrolimus, indicating that a PHOSITA would routinely use these methods to guide their formulation development. Therefore, arriving at the particular dissolution profile of Claim 1 would have been an obvious refinement of known extended-release tacrolimus formulations.

Claim 11 Obviousness Analysis: Conversion Method with Dose Reduction

Claim 11: A method for converting a transplant patient from a twice-daily immediate-release tacrolimus regimen (e.g., Prograf®) to a once-daily extended-release tacrolimus formulation, comprising administering a total daily dose of the extended-release formulation that is reduced by 20-34% compared to the previous total daily dose of the immediate-release product.

Combination of Prior Art: Prograf® in view of WO 2005/020993 and Advagraf® combined with routine clinical practice.

Prograf® (label April 27, 2006) represented the standard twice-daily immediate-release tacrolimus regimen, establishing baseline dosage and efficacy.
WO 2005/020993 (published March 10, 2005) explicitly taught that sustained-release tacrolimus formulations provide "improved bioavailability" compared to Prograf®. This document further states that "An increased bioavailability in combination with an extended release formulation may allow a reduction in the dosage units taken by a patient, e.g. down to a single dose daily".
Advagraf® (approved by EMEA April 23, 2007) confirmed the clinical availability of a once-daily extended-release tacrolimus product.
Routine clinical practice involves conducting dose-finding studies and establishing conversion protocols when a new drug formulation, particularly one with improved bioavailability, is introduced to ensure equivalent therapeutic effect and manage potential side effects.

Motivation and Rationale:
A PHOSITA would be motivated to develop a formal conversion strategy from immediate-release Prograf® to a once-daily extended-release formulation. The clear teaching in WO 2005/020993 regarding the "improved bioavailability" of extended-release tacrolimus and the statement that this "may allow a reduction in the dosage units" would naturally lead a PHOSITA to investigate dose reductions.

The specific range of "reduced by 20-34%" is an expected outcome within the context of dose adjustments for drugs exhibiting enhanced bioavailability. WO 2005/020993 (published prior to the priority date) suggested that improved formulations could achieve "a similar bioavailability and an improved profile after administration in a dose that is at the about most about 85% w/w ... of the dose of tacrolimus administered in the form of Prograf®". This statement anticipates a dose reduction of at least 15%. A PHOSITA would then conduct routine clinical studies to determine the precise dose conversion ratio, with a reasonable expectation of finding a reduction within this general range (e.g., 15-50%). Therefore, the specific range claimed in Claim 11 would be an obvious optimization based on the known pharmacokinetic improvements of extended-release tacrolimus.

Claim 15 Obviousness Analysis: Treatment of De Novo Transplant Patients with Specific AUC on Day 1

Claim 15: A method of treating a de novo transplant patient, comprising initiating treatment with a once-daily extended-release tacrolimus oral dosage form, wherein the dosage form provides a systemic drug exposure (AUC) on day 1 that is at least 70% of the exposure obtained at day 1 after administration of the same total daily dose of an immediate-release oral tacrolimus dosage form administered twice a day.

Combination of Prior Art: Prograf® in view of Advagraf® and WO 2005/020993/994, combined with a known clinical need.

Prograf® (label April 27, 2006) represented the established immediate-release regimen for transplant patients, setting the benchmark for systemic exposure in de novo patients.
Advagraf® (approved by EMEA April 23, 2007) introduced a once-daily extended-release tacrolimus formulation. Critically, the instant patent itself identifies a problem with Advagraf® in de novo patients, stating it provides "systemic exposure which is approximately 30% and 50% lower when compared with administration of the Prograf® formulation administered to de novo kidney and de novo liver transplant patients, respectively" on day 1. This explicitly highlights a deficiency in initial exposure for extended-release tacrolimus in a critical patient population.
WO 2005/020993 and WO 2005/020994 (published March 10, 2005) by the same inventors, taught various extended-release formulations designed to achieve "enhanced bioavailability" compared to Prograf®. These documents provided methods for formulating tacrolimus to improve its absorption.

Motivation and Rationale:
A PHOSITA would be strongly motivated to develop an improved extended-release tacrolimus formulation specifically for de novo transplant patients, given the known problem of reduced systemic exposure on day 1 with Advagraf®. The objective would be to achieve an initial exposure profile (AUC) in de novo patients that is at least comparable to immediate-release Prograf®, thereby ensuring effective immunosuppression from the outset.

Given the explicit problem identified with Advagraf® and the teachings in WO 2005/020993/994 regarding extended-release formulations with "enhanced bioavailability," it would be obvious for a PHOSITA to apply these formulation principles to create a once-daily extended-release product optimized to overcome Advagraf's deficiency in de novo patients. The specific target of "at least 70% of the exposure obtained at day 1 after administration of the same daily dose however administered as an immediate release oral dosage form administered twice a day" for de novo kidney transplant patients directly addresses the known shortcoming of Advagraf® (which showed a 30% lower exposure in de novo kidney patients compared to Prograf®). A PHOSITA, armed with knowledge of Advagraf®'s limitations and the formulation strategies for enhancing bioavailability from WO 2005/020993/994, would have a reasonable expectation of success in developing such a formulation through routine optimization to achieve the desired day 1 AUC in de novo patients. The patent itself underscores this motivation, stating that the invention's formulation is "capable of securing a sufficient systemic exposure even in the first 24 hours after initiation".